WO1999016891B1 - Methods of replicating virus in monocyte-derived macrophage cultures - Google Patents

Methods of replicating virus in monocyte-derived macrophage cultures

Info

Publication number
WO1999016891B1
WO1999016891B1 PCT/US1998/020749 US9820749W WO9916891B1 WO 1999016891 B1 WO1999016891 B1 WO 1999016891B1 US 9820749 W US9820749 W US 9820749W WO 9916891 B1 WO9916891 B1 WO 9916891B1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
hcv
hepatitis
human herpes
culture
Prior art date
Application number
PCT/US1998/020749
Other languages
French (fr)
Other versions
WO1999016891A1 (en
Inventor
Cecilia Soderberg-Naucler
Kenneth N Fish
Ashlee Moses
Daniel Streblow
Jay Nelson
Original Assignee
Univ Oregon Health Sciences
Soderberg Naucler Cecilia
Kenneth N Fish
Ashlee Moses
Daniel Streblow
Jay Nelson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health Sciences, Soderberg Naucler Cecilia, Kenneth N Fish, Ashlee Moses, Daniel Streblow, Jay Nelson filed Critical Univ Oregon Health Sciences
Priority to CA002305622A priority Critical patent/CA2305622A1/en
Priority to EP98949728A priority patent/EP1023451A4/en
Priority to AU95993/98A priority patent/AU738685B2/en
Priority to JP2000513960A priority patent/JP2001518306A/en
Publication of WO1999016891A1 publication Critical patent/WO1999016891A1/en
Publication of WO1999016891B1 publication Critical patent/WO1999016891B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material

Abstract

The present invention provides methods of latent virus reactivation in monocyte-drived macrophages through allogeneic stimulation of peripheral blood mononuclear cells ('PBMC'), methods of culturing virus, and cultures of virally permissive monocyte-derived macrophages.

Claims

AMENDED CLAIMS
[received by the International Bureau on 9 April 1999 (09.04.99); new claims 66-85 added; remaining claims unchanged (3 pages)]
66. The method of claim 1, wherein the virus is hepatitis C virus (HCV).
67. The method of claim 8, wherein the virus is hepatitis C virus (HCV).
68. The method of claim 21, wherein the virus is hepatitis C virus (HCV).
69. Tlie method of claim 38, wherein the virus is hepatitis C virus (HCV).
70. The method of claim 44, wherein the virus is hepatitis C virus (HCV).
71. The method of claim 51, wherein the virus is hepatitis C virus (HCV).
72. Virus made using the method of claim 1.
73. The virus of claim 72, wherein the virus is selected from the group consisting of cytomegalo virus (CMV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human herpes virus 6 (HHV6), human herpes virus 7 (HHV7), and human herpes virus 8 (HHV8).
74. Virus of claim 72, wherein the virus is hepatitis C virus (HCV).
75. Infective virus made using the method of claim 38.
76. The virus of claim 75, wherein the virus is selected from the group consisting of cytomcgaloviπis (CMV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human herpes virus 6 (HHV6), human herpes virus 7 (HHV7), and human herpes virus 8 (HHV8).
77. The virus of claim 75, wherein the virus is hepatitis C virus (HCV).
78. A method of infecting cells with virus, the method comprising the steps of:
(a) culturing monocytes under conditions where the monαcytes are in fluid communication with viable, allogeneically stimulated peripheral blood mononuclear cells (PBMC) to activate the monocytes to differentiate into virally permissive monocyte- derived macrophages;
(b) permitting virus replication in the monocyte-derived macrophages, where the virus is either latent in the monocytes or exogenously added to the culture;
(c) collecting virus from the culture; and (d) contacting a secoDd culture of cells with the virus, thereby infecting the cells with the virus.
79. The method of claim 78, wherein the second culture of cells comprises fibroblasts.
80. The method of claim 78, wherein the virus is selected from the group consisting of cytomegalovirus (CMV), hepatitis C virus (HCV), human immunodeficiency virus (HTV), human herpes virus 6 (HHV6), human herpes virus 7 (HHV7), and human herpes virus 8 (HHV8).
81. The method of claim 78, wherein the virus is hepatitis C virus (HCV).
82. A method of infecting cells with virus, the method comprising the steps of: (a) culturing CD14+ monocytes under conditions where the monocytes are exposed to conditioned media comprising IFNγ in an amount sufficient to activate the monocytes to differentiate into virally permissive monocyte-derived macrophages;
(b) permitting viral replication in the monocyte-derived macrophages, where the virus is either latent in the monocytes or exogenously added to the culture. (c) collecting virus from the culture; and
(d) contacting a second culture of cells with the virus, thereby infecting the cells with the virus.
83. The method of claim 82, wherein the second culture of cells comprises libroblasts.
84. The method of claim 82, wherein the virus is selected from the group consisting of cytomegalovirus (CMV), hepatitis C vims (HCV), human immunodeficiency virus (HIV), human herpes virus 6 (HHV6), human herpes virus 7 (HHV7), and human herpes virus 8 (HHV8).
85. The method of claim 82, wherein the virus is hepatitis C virus (HCV).
PCT/US1998/020749 1997-10-01 1998-09-30 Methods of replicating virus in monocyte-derived macrophage cultures WO1999016891A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002305622A CA2305622A1 (en) 1997-10-01 1998-09-30 Methods of replicating virus in monocyte-derived macrophage cultures
EP98949728A EP1023451A4 (en) 1997-10-01 1998-09-30 Methods of replicating virus in monocyte-derived macrophage cultures
AU95993/98A AU738685B2 (en) 1997-10-01 1998-09-30 Methods of replicating virus in monocyte-derived macrophage cultures
JP2000513960A JP2001518306A (en) 1997-10-01 1998-09-30 Methods for replicating viruses in cultures of monocyte-derived macrophages

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6058397P 1997-10-01 1997-10-01
US60/060,583 1997-10-01

Publications (2)

Publication Number Publication Date
WO1999016891A1 WO1999016891A1 (en) 1999-04-08
WO1999016891B1 true WO1999016891B1 (en) 1999-06-10

Family

ID=22030427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/020749 WO1999016891A1 (en) 1997-10-01 1998-09-30 Methods of replicating virus in monocyte-derived macrophage cultures

Country Status (6)

Country Link
US (2) US6225048B1 (en)
EP (1) EP1023451A4 (en)
JP (1) JP2001518306A (en)
AU (1) AU738685B2 (en)
CA (1) CA2305622A1 (en)
WO (1) WO1999016891A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1424390A4 (en) * 2001-08-06 2004-12-15 Yangling Daiying Biolog Engine The intact hepatitis c virus and the method for culturing it in a vitro cell culture
EP1463822B1 (en) * 2001-12-19 2011-10-26 The J. David Gladstone Institutes Method for the production of cell lines with latent immunodeficiency virus
US20030219407A1 (en) * 2002-05-15 2003-11-27 The Regents Of The University Of California RNA silencing in animals as an antiviral defense
WO2005017125A2 (en) * 2003-08-14 2005-02-24 California Institute Of Molecular Medicine Method for isolation and replication of infectious human hepatitis-c virus
US8123807B2 (en) * 2004-10-20 2012-02-28 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US8317864B2 (en) * 2004-10-20 2012-11-27 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US8167944B2 (en) 2004-10-20 2012-05-01 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US8128662B2 (en) 2004-10-20 2012-03-06 Vertiflex, Inc. Minimally invasive tooling for delivery of interspinous spacer
US9119680B2 (en) 2004-10-20 2015-09-01 Vertiflex, Inc. Interspinous spacer
US8152837B2 (en) 2004-10-20 2012-04-10 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US8945183B2 (en) 2004-10-20 2015-02-03 Vertiflex, Inc. Interspinous process spacer instrument system with deployment indicator
US8277488B2 (en) 2004-10-20 2012-10-02 Vertiflex, Inc. Interspinous spacer
US8012207B2 (en) * 2004-10-20 2011-09-06 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US8123782B2 (en) * 2004-10-20 2012-02-28 Vertiflex, Inc. Interspinous spacer
US9023084B2 (en) 2004-10-20 2015-05-05 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for stabilizing the motion or adjusting the position of the spine
US7763074B2 (en) 2004-10-20 2010-07-27 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US8409282B2 (en) 2004-10-20 2013-04-02 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US9161783B2 (en) 2004-10-20 2015-10-20 Vertiflex, Inc. Interspinous spacer
US8273108B2 (en) 2004-10-20 2012-09-25 Vertiflex, Inc. Interspinous spacer
US8425559B2 (en) 2004-10-20 2013-04-23 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US8613747B2 (en) 2004-10-20 2013-12-24 Vertiflex, Inc. Spacer insertion instrument
EP2219538B1 (en) 2004-12-06 2022-07-06 Vertiflex, Inc. Spacer insertion instrument
US8845726B2 (en) 2006-10-18 2014-09-30 Vertiflex, Inc. Dilator
WO2008130564A1 (en) 2007-04-16 2008-10-30 Vertiflex Inc. Interspinous spacer
US20100216116A1 (en) 2007-06-08 2010-08-26 Ghent University Viral latency model
WO2009091922A2 (en) 2008-01-15 2009-07-23 Vertiflex, Inc. Interspinous spacer
EP2512357B1 (en) 2009-12-15 2016-07-13 Vertiflex, Inc. Spinal spacer for cervical and other vertebra, and associated systems
US9675303B2 (en) 2013-03-15 2017-06-13 Vertiflex, Inc. Visualization systems, instruments and methods of using the same in spinal decompression procedures
AU2015256024B2 (en) 2014-05-07 2020-03-05 Vertiflex, Inc. Spinal nerve decompression systems, dilation systems, and methods of using the same

Also Published As

Publication number Publication date
EP1023451A4 (en) 2005-03-23
JP2001518306A (en) 2001-10-16
AU738685B2 (en) 2001-09-27
US6225048B1 (en) 2001-05-01
CA2305622A1 (en) 1999-04-08
AU9599398A (en) 1999-04-23
US20010055755A1 (en) 2001-12-27
EP1023451A1 (en) 2000-08-02
WO1999016891A1 (en) 1999-04-08

Similar Documents

Publication Publication Date Title
WO1999016891B1 (en) Methods of replicating virus in monocyte-derived macrophage cultures
Wilkie et al. Sequence arrangement in herpes simplex virus type 1 DNA: identification of terminal fragments in restriction endonuclease digests and evidence for inversions in redundant and unique sequences
Stinski Sequence of protein synthesis in cells infected by human cytomegalovirus: early and late virus-induced polypeptides
Lopez et al. Characteristics of human herpesvirus-6
Kikuta et al. Interferon induction by human herpesvirus 6 in human mononuclear cells
MY117686A (en) Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof
CA2064705A1 (en) Methods for Culturing HCV in Eukaryotic Cells
CA2072627A1 (en) Recombinant herpes simplex viruses vaccines and methods
NZ315357A (en) Method for industrially producing a japanese encephalitis vaccine, and resulting vaccine
Kreil et al. Viral infection of macrophages profoundly alters requirements for induction of nitric oxide synthesis
Ben-Porat et al. Origin of replication of the DNA of a herpesvirus (pseudorabies).
Yajima et al. Transforming activity of Epstein-Barr virus obtained by superinfection of Raji cells.
ATE277634T1 (en) ASSEMBLY-DEFICIENCY HERPES VIRUS AS A VACCINE
Ecker et al. Varicella-zoster virus vaccine DNA differs from the parental virus DNA
NO922422L (en) MATERIAL WITH ADHERENT BONDED CELLS, AND PROCEDURES FOR PRODUCING VIRUS / VIRUS ANTIGENS
AU8156594A (en) Non-A non-B sequences
CA2180346A1 (en) Herpesvirus pre-(viral dna replication) enveloped particles
DK0592636T3 (en) Process for Preparing a Viable Cell Culture Infected with a Disseminated Sclerosis
CA2400143A1 (en) Recombinant conglutinin and producing method thereof
Falk Jr A review of Herpesvirus papio, a B-lymphotropic virus of baboons related to EBV
Walz-Cicconi et al. Phosphonoacetic acid induced persistence of varicella-zoster virus in cell culture
Bucher et al. Maintenance of human cytomegalovirus genome in human diploid fibroblast cells
ZEIGEL et al. Characterization of Virus-like Particles Released from the Hamster: Cell Eine CHO-K1 After Treatment with 5-Bromodeoxyuridine. By KF MANLY, JF GIVENS, RL TA~ ER and
Bardy et al. Occurrence of Epstein-Barr Virus Deoxyribonuclease Enzyme Activity-Neutralizing Antibodies: An Index of Epstein-Barr Virus Disease
EP0236058A3 (en) Vaccine against herpes simplex

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2305622

Country of ref document: CA

Ref country code: CA

Ref document number: 2305622

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 513960

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 95993/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998949728

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998949728

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 95993/98

Country of ref document: AU